METABOLIC & WEIGHT RESEARCH / COMPARE
Two Incretins, Side by Side
Where retatrutide and tirzepatide share pharmacology, where they differ, and what the current evidence actually shows for each.
The short version
This page lines up retatrutide and tirzepatide on the dimensions that matter when reading the research: receptor targets, evidence depth, regulatory standing, and the single most important caution for each. The headline: both are synthetic incretin-class peptides acylated for once-weekly subcutaneous dosing; tirzepatide is FDA-approved across three indications with multiple completed Phase 3 programs; retatrutide adds a glucagon receptor to the dual-receptor scaffold of tirzepatide and is still in Phase 3, with no regulatory approval as of mid-2026 [1][4][9][11]. Neither is presented here with a human dose.
The comparison matrix
| Dimension | Retatrutide | Tirzepatide |
|---|---|---|
| Peptide class | Triple GIP/GLP-1/glucagon receptor agonist (investigational, 39 aa) | Dual GIP/GLP-1 receptor agonist (FDA-approved, 39 aa) |
| Most-studied in | Obesity, type 2 diabetes, MASLD (Phase 1/2 trials) | Type 2 diabetes, obesity, obstructive sleep apnea (Phase 3 + approved) |
| Evidence base (model) | Phase 2 RCTs; Phase 3 (TRIUMPH) ongoing [1][4][5] | Multiple Phase 3 RCTs completed; head-to-head evidence available [8][11][12] |
| Administration studied | Subcutaneous once weekly (trials: 1, 4, 8, 12 mg doses) [4][6] | Subcutaneous once weekly (approved: 2.5–15 mg escalation schedule) [9] |
| Regulatory status | Investigational. Not approved by FDA or any regulator as of mid-2026 [1] | FDA-approved: T2D (2022), obesity/overweight (2023), obstructive sleep apnea (subsequent) [9] |
| Key caution | No approved indication; unregulated gray-market supply; cardiovascular outcomes data pending [1][4] | Gallbladder/biliary disease signal (RR 1.97 in meta-analysis); lean-mass loss; weight regain on discontinuation [10] |
Peptide class
Both compounds are 39-amino-acid synthetic peptides acylated with a fatty-diacid moiety for albumin binding and extended half-life, enabling once-weekly dosing. The structural difference is one receptor: tirzepatide agonizes GIP and GLP-1; retatrutide adds glucagon receptor agonism to those two. The glucagon arm adds thermogenic energy expenditure and lipid mobilization — the component that is absent from tirzepatide's pharmacology [1][2][9]. Relative to their native hormones, retatrutide is approximately 8.9× more potent at GIPR, 0.3× at GCGR, and 0.4× at GLP-1R; tirzepatide's GIPR activity is also higher than native GIP, a pharmacological advance over selective GLP-1 agents [2][9].
Most-studied in
Both are studied in metabolic disease, but trial breadth differs substantially. Tirzepatide has completed Phase 3 programs in type 2 diabetes (SURPASS series), obesity without diabetes (SURMOUNT series), and obstructive sleep apnea, with a head-to-head obesity trial against a higher dose of another approved incretin [8][11][12]. Retatrutide's evidence comes from Phase 2 obesity and type 2 diabetes RCTs and a Phase 2 MASLD substudy [3][4][5], with all pivotal Phase 3 data still pending [1]. Liver-fat reduction (−82.4% at 24 weeks in the MASLD substudy) is a signal that retatrutide has developed further than tirzepatide has in that particular indication [3].
Evidence base (model)
Tirzepatide has the deeper controlled human evidence. The SURMOUNT-1 trial alone enrolled 2,539 participants and ran 72 weeks; SURPASS-2 included 1,879 adults with T2D; and SURMOUNT-5 directly compared tirzepatide and semaglutide in 751 people with obesity [8][11][12]. Retatrutide's Phase 2 obesity trial enrolled 338 participants over 48 weeks, and its T2D trial 281 over 36 weeks [4][5]. Phase 2 data are informative but not sufficient to characterize the full safety and durability profile that Phase 3 programs provide — a gap that will close only when TRIUMPH reports [1].
Administration studied
Both compounds are administered subcutaneously, once weekly. Trial doses for retatrutide spanned 1, 4, 8 and 12 mg; the first-in-human study characterized a half-life of approximately 6 days supporting that schedule [4][6]. Tirzepatide's approved titration runs from 2.5 mg at initiation up to 15 mg maintenance; the approximately 5-day half-life is the pharmacokinetic basis for the weekly schedule [9].
Regulatory status
The regulatory gap between the two is the sharpest distinction on this desk. Tirzepatide is FDA-approved for three indications — type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea — and is available as a prescription medicine in the United States and other jurisdictions [9]. Retatrutide is investigational. It has no approved indication, no prescription pathway, and Phase 3 outcome trials are ongoing with no reported results as of mid-2026 [1]. Material labeled as retatrutide in the gray market is unregulated and of unverified identity and purity.
Key caution
For retatrutide the defining caution is regulatory: it is not approved, Phase 3 is incomplete, long-term cardiovascular and renal outcomes are unknown, and any material outside a clinical trial is unverified [1][4]. For tirzepatide the most clinically salient signal is gallbladder and biliary disease — a statistically significant increase (RR 1.97) across meta-analyzed RCTs — alongside a well-documented lean-mass reduction and substantial weight regain upon discontinuation [10]. Both share GI intolerance as the principal tolerability challenge, and both carry heart-rate and drug-interaction considerations [4][9][10]. Reading them together, the distinction is between an approved agent with a well-characterized benefit-risk profile and an investigational agent whose Phase 3 program will determine whether its larger weight-reduction signal comes at acceptable cost.